$2.34 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter

Analysts expect Boston Scientific Corporation (NYSE:BSX) to report $2.34 billion in sales for the current quarter, according to Zacks. Eight analysts have issued estimates for Boston Scientific’s earnings, with the lowest sales estimate coming in at $2.32 billion and the highest estimate coming in at $2.36 billion. Boston Scientific posted sales of $2.16 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The business is scheduled to announce its next earnings report on Thursday, April 26th.

On average, analysts expect that Boston Scientific will report full-year sales of $2.34 billion for the current year, with estimates ranging from $9.70 billion to $9.77 billion. For the next fiscal year, analysts anticipate that the company will post sales of $10.32 billion per share, with estimates ranging from $9.90 billion to $10.54 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Boston Scientific.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.34. The company had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.30 EPS.

BSX has been the topic of several analyst reports. BMO Capital Markets lifted their price target on Boston Scientific from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. SunTrust Banks set a $33.00 price target on Boston Scientific and gave the stock a “buy” rating in a report on Monday, December 4th. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price target on the stock in a report on Friday, October 20th. Evercore ISI initiated coverage on Boston Scientific in a report on Wednesday, January 3rd. They set an “in-line” rating and a $27.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $31.00.

Boston Scientific (NYSE BSX) opened at $25.92 on Monday. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $35,590.00, a price-to-earnings ratio of 370.29, a price-to-earnings-growth ratio of 1.88 and a beta of 0.81. Boston Scientific has a fifty-two week low of $23.29 and a fifty-two week high of $29.93.

In other news, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the company’s stock in a transaction on Tuesday, November 28th. The stock was bought at an average cost of $0.45 per share, with a total value of $183,602.70. Also, SVP David A. Pierce sold 5,152 shares of Boston Scientific stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the transaction, the senior vice president now directly owns 38,116 shares of the company’s stock, valued at $1,029,132. The disclosure for this sale can be found here. Insiders have sold a total of 161,464 shares of company stock valued at $4,253,617 over the last three months. Corporate insiders own 0.74% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Cerebellum GP LLC acquired a new position in Boston Scientific in the 4th quarter valued at about $126,000. Valeo Financial Advisors LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $138,000. Steward Partners Investment Advisory LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $139,000. Ironwood Investment Counsel LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $204,000. Finally, Perkins Capital Management Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at about $204,000. 90.15% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “$2.34 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/12/2-34-billion-in-sales-expected-for-boston-scientific-corporation-bsx-this-quarter.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply